You have 9 free searches left this month | for more free features.

epirubicin

Showing 1 - 25 of 173

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Breast Tumors Trial in Shanghai (Epirubicin, Docetaxel, cyclophosphamide)

Completed
  • Breast Neoplasms
  • Epirubicin
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Oct 26, 2022

Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023

Soft Tissue Sarcoma Trial in Beijing, Shanghai (Anlotinib HCl capsule, Epirubicin, Arotinib HCl capsule )

Recruiting
  • Soft Tissue Sarcoma
  • Anlotinib hydrochloride capsule
  • +2 more
  • Beijing, Beijing, China
  • +2 more
Feb 16, 2022

Sepsis Trial in Germany (Epirubicin, Placebo)

Not yet recruiting
  • Sepsis
  • Epirubicin
  • Placebo
  • Jena, Thuringia, Germany
  • +4 more
Feb 25, 2022

Breast Cancer, TNBC - Triple-Negative Breast Cancer Trial (Toripalimab, Epirubicin, High Intensity Focused Ultrasoun)

Not yet recruiting
  • Breast Cancer
  • TNBC - Triple-Negative Breast Cancer
  • (no location specified)
Aug 5, 2022

Hepatocellular Carcinoma Trial in Hangzhou (Idarubicin Hydrochloride for Injection, Epirubicin)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Idarubicin Hydrochloride for Injection
  • Epirubicin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Sep 13, 2021

Breast Tumors Trial in Guangzhou (Trilaciclib, Epirubicin, Cyclophosphamide)

Not yet recruiting
  • Breast Neoplasms
  • Guangzhou, Gangdong, China
    Sun-yat sen university cancer center
Jul 30, 2023

Breast Cancer Trial in Hangzhou (Docetaxel, Carboplatin, Trastuzumab)

Recruiting
  • Breast Cancer
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jun 28, 2022

Breast Cancer Trial in Hangzhou (Docetaxel, Carboplatin, Trastuzumab)

Recruiting
  • Breast Cancer
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jun 28, 2022

Breast Cancer Trial (Gemcitabine, Epirubicin, Docetaxel)

Completed
  • Breast Cancer
  • (no location specified)
Oct 4, 2021

Breast Tumors Trial in Saint Louis (Doxorubicin, Trastuzumab, Cyclophosphamide)

Terminated
  • Breast Neoplasms
  • Saint Louis, Missouri
    Washington University School of Medicine
Oct 31, 2022

Bladder Cancer, Non-muscle Invasive Trial in Biel (Epirubicin, Mitomycin, Gemcitabine)

Recruiting
  • Bladder Cancer
  • Non-muscle Invasive
  • Epirubicin
  • +3 more
  • Biel, Switzerland
    Roland Seiler
Nov 17, 2022

Diffuse Large B Cell Lymphoma Trial in Shenyang (Zanubrutinib, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Shenyang, Liaoning, China
    Xing Xiaojing
Jun 1, 2023

Breast Cancer Trial in Houston (Panitumumab, Nab-paclitaxel, Carboplatin)

Completed
  • Breast Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 20, 2022

Breast Cancer Trial in Shanghai (Pegylated liposomal doxorubicin, Epirubicin, Cyclophosphamid)

Recruiting
  • Breast Cancer
  • Pegylated liposomal doxorubicin
  • +5 more
  • Shanghai, China
    Shanghai Pudong Hospital
Dec 11, 2022

Breast Cancer, Neoadjuvant Therapy Trial in Beijing (Utidelone, Carboplatin, Epirubicin)

Not yet recruiting
  • Breast Cancer
  • Neoadjuvant Therapy
  • Beijing, Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Aug 1, 2023

pCR Rate, BCT Rate, Safety Trial in Linyi, Shanghai (Metformin, Docetaxel, Epirubicin)

Terminated
  • pCR Rate
  • +2 more
  • Linyi, Shandong, China
  • +1 more
Mar 28, 2022

Breast Tumors Trial in Guangzhou (procedure, drug, biological)

Recruiting
  • Breast Neoplasms
  • Sentinel Lymph Node Biopsy (SLNB)
  • +7 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Nov 2, 2023

Hepatocellular Carcinoma Trial in Nanjing (cTACE, Dicycloplatin (TP21), Epirubicin)

Recruiting
  • Hepatocellular Carcinoma
  • cTACE
  • +2 more
  • Nanjing, Jiangsu, China
    Zhongda Hospital, Southeast University
Jul 22, 2022

HER2-negative Breast Cancer, Neoadjuvant Chemo Trial in Hangzhou (Epirubicin, Cyclophosphamid, Docetaxel)

Recruiting
  • HER2-negative Breast Cancer
  • Neoadjuvant Chemotherapy
  • Epirubicin
  • +3 more
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Aug 9, 2021

Breast Tumors Trial in Guangzhou (procedure, drug, biological)

Recruiting
  • Breast Neoplasms
  • Sentinel Lymph Node Biopsy (SLNB)
  • +7 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Jul 31, 2023

Breast Cancer Trial in United States (Gemcitabine, Epirubicin, Albumin-bound Paclitaxel)

Completed
  • Breast Cancer
  • Fort Myers, Florida
  • +12 more
Nov 22, 2021

Diffuse Large B-cell Lymphoma Trial in Shanghai (Rituximab, Cyclophosphamide, Epirubicin)

Active, not recruiting
  • Diffuse Large B-cell Lymphoma
  • Shanghai, Shanghai, China
    Shanghai Ruijin Hospital
Dec 1, 2022

Marginal Zone Lymphoma Trial in Zhengzhou (Bortezomib, Rituximab, Epirubicin)

Recruiting
  • Marginal Zone Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Aug 15, 2021

HER2 Positive Early Breast Cancer Trial in Shanghai (Docetaxel, carboplatin, Trastuzumab)

Recruiting
  • HER2 Positive Early Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Jun 6, 2023